[go: up one dir, main page]

DK3570819T3 - Medicinsk behandling omfattende enteral indgivelse af edaravone - Google Patents

Medicinsk behandling omfattende enteral indgivelse af edaravone Download PDF

Info

Publication number
DK3570819T3
DK3570819T3 DK17737775.1T DK17737775T DK3570819T3 DK 3570819 T3 DK3570819 T3 DK 3570819T3 DK 17737775 T DK17737775 T DK 17737775T DK 3570819 T3 DK3570819 T3 DK 3570819T3
Authority
DK
Denmark
Prior art keywords
edaravone
medical treatment
enteral administration
enteral
administration
Prior art date
Application number
DK17737775.1T
Other languages
English (en)
Inventor
Sytske Hyke Moolenaar
Original Assignee
Treeway Tw001 B V
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Treeway Tw001 B V filed Critical Treeway Tw001 B V
Application granted granted Critical
Publication of DK3570819T3 publication Critical patent/DK3570819T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4151,2-Diazoles
    • A61K31/41521,2-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. antipyrine, phenylbutazone, sulfinpyrazone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1617Organic compounds, e.g. phospholipids, fats
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1611Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1617Organic compounds, e.g. phospholipids, fats
    • A61K9/1623Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1629Organic macromolecular compounds
    • A61K9/1641Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2009Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2013Organic compounds, e.g. phospholipids, fats
    • A61K9/2018Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/2031Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0087Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Inorganic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Vascular Medicine (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Transplantation (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
DK17737775.1T 2017-01-17 2017-07-06 Medicinsk behandling omfattende enteral indgivelse af edaravone DK3570819T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP17151741 2017-01-17
PCT/EP2017/067005 WO2018133957A1 (en) 2017-01-17 2017-07-06 Medical treatment comprising enteral administration of edaravone

Publications (1)

Publication Number Publication Date
DK3570819T3 true DK3570819T3 (da) 2021-04-06

Family

ID=57850912

Family Applications (1)

Application Number Title Priority Date Filing Date
DK17737775.1T DK3570819T3 (da) 2017-01-17 2017-07-06 Medicinsk behandling omfattende enteral indgivelse af edaravone

Country Status (12)

Country Link
US (1) US10966960B2 (da)
EP (1) EP3570819B1 (da)
JP (1) JP6898027B2 (da)
AU (1) AU2017394478B2 (da)
BR (1) BR112019014712A2 (da)
CA (1) CA3050031A1 (da)
DK (1) DK3570819T3 (da)
ES (1) ES2868955T3 (da)
MX (1) MX390101B (da)
PL (1) PL3570819T3 (da)
PT (1) PT3570819T (da)
WO (1) WO2018133957A1 (da)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2017394478B2 (en) 2017-01-17 2023-07-20 Treeway Tw001 B.V. Medical treatment comprising enteral administration of edaravone
JP7277005B2 (ja) 2017-07-06 2023-05-18 ツリーウェイ ティーダブリュー001 ビー.ブイ. 酸化ストレス媒介性の神経変性障害の経口治療におけるエダラボンの使用
US11826352B2 (en) 2018-11-02 2023-11-28 Mitsubishi Tanabe Pharma Corporation Edaravone suspension for oral administration
SG11202104365QA (en) 2018-11-02 2021-05-28 Mitsubishi Tanabe Pharma Corp Edaravone suspension for oral administration
US12343330B2 (en) 2023-02-16 2025-07-01 Slayback Pharma Llc Stable pharmaceutical compositions of edaravone

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3758164B2 (ja) 2000-10-24 2006-03-22 三菱ウェルファーマ株式会社 筋萎縮性側索硬化症(als)治療剤
IS7278A (is) 2001-11-26 2003-05-27 Merlyn Associates, Inc. Barkaslanga með stefnustjórnanlegum enda og stöðuhaldandi búnaði
CN1241565C (zh) * 2003-04-16 2006-02-15 浙江震元制药有限公司 依达拉奉药物组合物及制备
CN100358520C (zh) 2003-09-11 2008-01-02 彭建华 具有良好稳定性的注射用依达拉奉粉针剂及其制备方法
ES2673158T3 (es) 2004-02-09 2018-06-20 Mitsubishi Tanabe Pharma Corporation Nuevo agente terapéutico para la esclerosis lateral amiotrófica (ELA) o enfermedad atribuible a ELA
CN101953832B (zh) 2010-08-10 2012-02-15 南京师范大学 β-环糊精包合依达拉奉的口服药物组合物及其制备方法
CN102349893A (zh) * 2011-08-19 2012-02-15 福建天泉药业股份有限公司 依达拉奉药物组合物
KR20190049905A (ko) 2011-09-05 2019-05-09 미쓰비시 타나베 파마 코퍼레이션 근위축성 측색경화증의 치료 또는 병세 진전 억제를 위한 약제
CN103251554A (zh) 2013-06-06 2013-08-21 南京亿华药业有限公司 一种稳定的依达拉奉注射液及其制备方法
CN113768879A (zh) 2016-03-16 2021-12-10 苏州澳宗生物科技有限公司 依达拉奉剂型
AU2017394478B2 (en) 2017-01-17 2023-07-20 Treeway Tw001 B.V. Medical treatment comprising enteral administration of edaravone
ES2850873T3 (es) 2017-01-17 2021-09-01 Treeway Tw001 B V Tratamiento que comprende la administración oral o gástrica de edaravona
JP7277005B2 (ja) 2017-07-06 2023-05-18 ツリーウェイ ティーダブリュー001 ビー.ブイ. 酸化ストレス媒介性の神経変性障害の経口治療におけるエダラボンの使用

Also Published As

Publication number Publication date
PT3570819T (pt) 2021-04-20
JP6898027B2 (ja) 2021-07-07
US10966960B2 (en) 2021-04-06
EP3570819B1 (en) 2021-03-03
EP3570819A1 (en) 2019-11-27
US20190328711A1 (en) 2019-10-31
AU2017394478A1 (en) 2019-08-01
JP2020506958A (ja) 2020-03-05
CA3050031A1 (en) 2018-07-26
BR112019014712A2 (pt) 2020-02-18
PL3570819T3 (pl) 2021-10-25
ES2868955T3 (es) 2021-10-22
MX390101B (es) 2025-03-20
MX2019008482A (es) 2019-11-11
WO2018133957A1 (en) 2018-07-26
AU2017394478B2 (en) 2023-07-20

Similar Documents

Publication Publication Date Title
IL264644B (en) Therapeutic compounds useful for the prophylactic or therapeutic treatment of an hiv virus infection
MA46284A (fr) Canule cardiaque
DK3244948T3 (da) Bestemmelse af medikamentdosis
EP3294212A4 (en) DRUG DELIVERY FROM HYDROGEL
EP3875139C0 (en) TREATMENT OF VENOUS DISEASES
DK3519018T3 (da) Medikamentadministrationsanordning
DK4335517T3 (da) Indgivelse og dosering af diaminofenothiaziner
EP3723692A4 (en) MEDICAL ASSISTANT
DK3551181T3 (da) Behandling omfattende oral eller gastrisk indgivelse af edaravone
DK3496783T3 (da) Medikamentadministrationsanordning
EP3681509C0 (en) WOUND REMEDY
DK3400045T3 (da) Medikamentadministrationsanordning
IT201600129679A1 (it) Capsula ingeribile per il trattamento fototerapico di infezioni
PL3600374T3 (pl) Leczenie zakażenia układu oddechowego
DK3294283T3 (da) Sacubitril-valsartan-doseringsregime til behandling af hjerteinsufficiens
DK3548061T3 (da) Behandling af neurologiske sygdomme
PL3646329T3 (pl) Układ do dostarczania pacjentowi wielu infuzji
DK3570819T3 (da) Medicinsk behandling omfattende enteral indgivelse af edaravone
DK3461516T3 (da) Medicinsk infusionsindretning
PL3204030T3 (pl) Terapia skojarzona zakażenia hbv i hdv
EP3368133A4 (en) ARTERIOVENOUS SHUNT WITH MEDICATION-TREATED BALLOON CATHETER
DK3403674T3 (da) Farmaceutiske sammensætninger til behandling af smerte
EP3313390A4 (en) INTRAVENOUS ADMINISTRATION OF CITRULLIN DURING SURGICAL PROCEDURE
IL261116A (en) A drug for the treatment of diabetic foot infections
DK3416654T3 (da) Medicinsk anvendelse af 5'-adenosindiphosphatribose (adpr)